Received Mar 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | XN575 | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | XN575 | — |
accidental administartion of Two Boostrix doses given at one instance; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of accidental overdose in a 53-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number XN575, expiry date 22-MAR-2027) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) (batch number XN575, expiry date 22-MAR-2027) for prophylaxis. On 05-MAR-2025, the patient received the 2nd dose of Boostrix and the 1st dose of Boostrix. On 05-MAR-2025, an unknown time after receiving Boostrix and not applicable after receiving Boostrix, the patient experienced accidental overdose (Verbatim: accidental administartion of Two Boostrix doses given at one instance). The outcome of the accidental overdose was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 05-MAR-2025 The pharmacist called in to request data about the recommendations following the accidental administration of 2 doses of Boostrix at one which led to Accidental overdose and asked if Shingrix can be given in such scenario. The vaccine administration facility was the same as primary reporter.